Dysregulation of mTOR signaling is implicated in various human diseases, including cancer, diabetes, neurodegeneration, and cardiovascular diseases. Overactivation of mTORC1 is commonly observed in cancers, where it promotes uncontrolled cell proliferation and survival. Conversely, mTOR inhibitors like rapamycin are being explored for their potential therapeutic benefits in treating these conditions.
